Sarkom

Sarkom. It is a broad category of malignant tumors arising from transformed cells of mesenchymal origin, which includes connective tissues such as bone, cartilage, fat, muscle, and blood vessels. These cancers are distinct from the more common carcinomas, which originate in epithelial tissues, and represent a significant challenge in oncology due to their diversity and relative rarity. The management of these tumors typically involves a multidisciplinary approach at specialized centers like the Memorial Sloan Kettering Cancer Center or the MD Anderson Cancer Center.

Definition and Classification

The term encompasses a heterogeneous group of over 70 histologic subtypes, broadly divided into bone sarcomas and soft tissue sarcomas. Classification is primarily based on the presumed tissue of origin, as outlined by the World Health Organization classification of tumours. Major categories include tumors resembling adipose tissue like liposarcoma, those of smooth muscle such as leiomyosarcoma, and those of bone like osteosarcoma. Other notable entities are gastrointestinal stromal tumor (GIST), Ewing sarcoma, and rhabdomyosarcoma, the latter being more common in children. This complex taxonomy is critical for determining prognosis and guiding therapy, with diagnostic confirmation often requiring expert pathologic review at institutions like the Armed Forces Institute of Pathology.

Causes and Risk Factors

Most cases arise sporadically from acquired genetic mutations, though specific etiologies are often unidentified. Known risk factors include prior exposure to ionizing radiation, such as from treatment for Hodgkin lymphoma, and chronic lymphedema, as seen in Stewart-Treves syndrome. Several hereditary cancer predisposition syndromes significantly elevate risk, including Li-Fraumeni syndrome (associated with TP53 mutations), Neurofibromatosis type 1 (linked to malignant peripheral nerve sheath tumor), and Retinoblastoma (which predisposes to osteosarcoma). Environmental exposures, such as to vinyl chloride or dioxin, have been linked to specific subtypes like angiosarcoma of the liver.

Symptoms and Diagnosis

Presentation is often insidious, with a painless, enlarging mass being the most common initial symptom; pain may occur if the tumor impinges on nerves or bone. Diagnosis begins with medical imaging, typically magnetic resonance imaging for soft tissue lesions or computed tomography and X-ray for bone lesions. The definitive diagnostic procedure is a biopsy, which must be carefully planned to avoid compromising future surgical resection. Pathologic analysis, which may include immunohistochemistry and molecular studies for translocations like the EWSR1-FLI1 fusion in Ewing sarcoma, is essential for accurate subtyping and staging, often involving systems like the American Joint Committee on Cancer staging system.

Treatment and Management

The cornerstone of curative treatment for localized disease is complete surgical resection with negative margins, often performed by specialized surgeons at centers like the Mayo Clinic. Radiation therapy, including techniques like intensity-modulated radiation therapy, is frequently used pre- or post-operatively to improve local control. Chemotherapy, with agents such as doxorubicin and ifosfamide, plays a central role in treating Ewing sarcoma and osteosarcoma, and is used for advanced or metastatic disease. For specific subtypes, targeted therapy (e.g., imatinib for GIST) and immunotherapy are emerging options. Clinical trials conducted through cooperative groups like the Children's Oncology Group are vital for advancing care.

Prognosis and Epidemiology

Overall, these tumors account for approximately 1% of adult malignancies but about 15% of pediatric cancers, with an incidence in the United States of around 16,000 new cases annually. Prognosis is highly variable, depending on factors such as histologic grade, tumor size, location, and the presence of metastasis, commonly to the lungs. Five-year survival rates for localized disease can exceed 70% but drop significantly for metastatic presentation. Epidemiological patterns vary globally, and research initiatives like the Surveillance, Epidemiology, and End Results program track outcomes. Advances in molecular biology and collaborative efforts through organizations like the Connective Tissue Oncology Society continue to refine prognostic understanding and therapeutic strategies. Category:Oncology Category:Pathology